All Stories

  1. Immune boosting to combat Alzheimer's disease: Position statement
  2. a vaccine prevents loss of cognition.
  3. Vaccines can prevent dementia
  4. Vaccines and dementia
  5. Bacillus Calmette–Guérin in Immuno-Regulation of Alzheimer’s Disease
  6. Evaluation of BCG Vaccination and Plasma Amyloid: A Prospective, Pilot Study with Implications for Alzheimer’s Disease
  7. Adult Vaccination, Getting to Know Their Nonspecific Effects
  8. Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease
  9. Poly(Vinyl Alcohol)‐Hydrogel Microparticles with Soft Barrier Shell for the Encapsulation of Micrococcus luteus
  10. Bladder Cancer Immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer‘s disease
  11. Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer’s disease in bladder cancer patients
  12. Can immunization with Bacillus Calmette-Guérin (BCG) protect against Alzheimer’s disease?
  13. BCG vaccination for bovine tuberculosis; conclusions from the Jerusalem One Health workshop
  14. Biosorption of copper from aqueous environments by Micrococcus luteus in cell suspension and when encapsulated
  15. Evolutionary Genomics and Conservation of the Endangered Przewalski’s Horse
  16. Living Composites of Electrospun Yeast Cells for Bioremediation and Ethanol Production
  17. Evolutionary changes in the genome of Mycobacterium tuberculosis and the human genome from 9000 years BP until modern times
  18. Living Composites of Bacteria and Polymers as Biomimetic Films for Metal Sequestration and Bioremediation
  19. Why Greenblatt?
  20. Blocked Bacteria Escape by ATRP Grafting of a PMMA Shell on PVA Microparticles
  21. Simultaneous detection of <I>Mycobacterium bovis</I> and <I>M. tuberculosis</I> in an apparently immunocompetent patient [Correspondence]
  22. Mycobacterium tuberculosis Complex Lipid Virulence Factors Preserved in the 17,000-Year-Old Skeleton of an Extinct Bison, Bison antiquus
  23. Rapid Differentiation of Mycobacterium tuberculosis and M. bovis by High-Resolution Melt Curve Analysis
  24. Pulmonary tuberculosis in the West Bank, Palestinian Authority: molecular diagnostic approach
  25. Rapid Differentiation of Mycobacterium tuberculosis and M. bovis by High-Resolution Melt Curve Analysis
  26. Molecular Exploration of the First-Century Tomb of the Shroud in Akeldama, Jerusalem
  27. Biomolecular archaeology of ancient tuberculosis: response to “Deficiencies and challenges in the study of ancient tuberculosis DNA” by Wilbur et al. (2009)
  28. Genome Sequence of the Fleming Strain of Micrococcus luteus, a Simple Free-Living Actinobacterium
  29. Structural Changes and Cellular Localization of Resuscitation-Promoting Factor in Environmental Isolates of Micrococcus luteus
  30. Detection and Molecular Characterization of 9000-Year-Old Mycobacterium tuberculosis from a Neolithic Settlement in the Eastern Mediterranean
  31. Attempts to revive Mycobacterium tuberculosis from 300-year-old human mummies
  32. Microsatellite genotyping of cultivars of the Holy Land grapevine, Vitis vinifera ssp. sativa (Vitaceae)
  33. Mode of Action of Fenarimol Against Leishmania Spp.
  34. A PCR method for detection of plant meals from the guts of insects
  35. Leishmaniasis in Ancient Egypt and Upper Nubia
  36. Short Communication: Palestinian infantile visceral leishmaniasis caused by a genetic variant of Leishmania infantum belonging to a new zymodeme
  37. Co–infection ofMycobacterium tuberculosisandMycobacterium lepraein human archaeological samples: a possible explanation for the historical decline of leprosy
  38. Genetic and biological diversity among populations of Leishmania major from Central Asia, the Middle East and Africa
  39. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA
  40. Micrococcus luteus - Survival in Amber
  41. Polymorphism among alleles of the 6-Phosphogluconate dehydrogenase gene from Leishmania major and Leishmania tropica
  42. Epidemiology of visceral leishmaniasis in the Jenin District, West Bank: 1989-1998.
  43. Genetic evidence for the origin of the agrimi goat (Capra aegagrus cretica)
  44. Mycobacterium tuberculosisComplex DNA from an Extinct Bison Dated 17,000 Years before the Present
  45. THE GENETIC SIGNATURE OF THE DEAD SEA SCROLLS
  46. Diversity of Microorganisms Isolated from Amber
  47. Determining the Sex of Infanticide Victims from the Late Roman Era through Ancient DNA Analysis
  48. DNA analysis reveals the sex of infanticide victims
  49. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine
  50. Analysis of Parchment Fragments from the Judean Desert Using DNA Techniques
  51. Sex identification of archaeological human remains based on amplification of the X and Y amelogenin alleles
  52. Cutaneous leishmaniasis: The prospects for a killed vaccine
  53. Leishmania major: glycolipid antigens recognized by immune human sera
  54. Development of Sandfly Forms of Leishmania major in Sucrose Solutions
  55. Cultivation of Besnoitia besnoiti and evaluation of susceptibility of laboratory animals to cultured parasites
  56. Leishmania major: Solid phase radioimmunoassay for antibody detection in human cutaneous leishmaniasis
  57. Parasite immunology and lymphocyte population dynamics
  58. Lipid and Lipopolysaccharide‐Like Antigens of Leishmania Promastigotes1
  59. Specific antibodies to precipitated from serum of cattle by live parasites and by soluble antigen
  60. C-Reactive Protein Binds Leishmanial Excreted Factors
  61. Interaction of aminoglycosides and ionophores in the killing ofCrithidia fasciculata
  62. Phenotypic diversity of cloned lines ofLeishmania major promastigotes
  63. Enzyme linked immunosorbent assay for detection of antibodies againstBesnoitia besnoiti in cattle
  64. Leishmania tropica: Protective response in C3H mice vaccinated with excreted factor crosslinked with the synthetic adjuvant, muramyl dipeptide
  65. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.
  66. An amphipathic sulphated glycoconjugate of Leishmania: characterization with monoclonal antibodies.
  67. Growth inhibition ofLeishmania tropicaamastigotesin vitroby rifampicin combined with amphotericin B
  68. Leishmanial excreted factors (EF) are distinguished by characteristic electrophoretic mobilities
  69. Surface reaction ofLeishmania
  70. Monoclonal antibodies for serotyping Leishmania strains
  71. The cellular and humoral immune response in subjects vaccinated against cutaneous leishmaniasis using Leishmania tropica major promastigotes
  72. Leishmania tropica and Leishmania donovani: Solid phase radioimmunoassay using leishmanial excreted factor
  73. Action of leishmanial excreted factor (EF) on human lymphocyte blast transformation
  74. Binding ofLeishmania promastigotes to macrophages
  75. Frozen stored Leishmania tropica vaccine: the effects of dose, route of administration and storage on the evolution of the clinical lesion. Two field trials in the Israel Defense Forces
  76. Leishmanial excreted factors (EFs): Purification by affinity chromatography
  77. Therapeutic Effect of Rifampicin and Isoniazid against Leishmania tropica major
  78. Surface reaction ofLeishmania
  79. Age-related changes in rat liver total protein and transferrin synthesis
  80. Identification of galactose as the immunodominant sugar of leishmanial excreted factor and subsequent labeling with galactose oxidase and sodium boro[3H]hydride
  81. Rifampicin Treatment of Cutaneous Leishmaniasis
  82. Surface reaction ofLeishmania
  83. Cellular changes in bone marrow of malaria-infected mice
  84. Ultrastructural characteristics of cell division in
  85. DO LEISHMANIA SEROTYPES MIMIC HUMAN BLOOD GROUP ANTIGENS?
  86. Adoptive transfer of immunity toPlasmodium berghei after busulfan and cyclophosphamide treatment of recipient mice
  87. Inhibitory activity of sinefungin and siba (5′‐deoxy‐5′‐S‐isobutylthio‐adenosine) on the growth of promastigotes and amastigotes of different species of leishmania
  88. Cellular changes in the bone marrow of Plasmodium berghei-infected mice
  89. An improved protocol for the preparation of a frozen promastigote vaccine for cutaneous leishmaniasis
  90. Production and secretion of Leishmania braziliensis proteins
  91. Leishmania spp.: Cellular levels and synthesis of polyamines during growth cycles
  92. Leishmania spp.: Effect of inhibitors on growth and on polyamine and macromolecular syntheses
  93. Leishmanial Excreted Factor: Protein-Bound and Free Forms from Promastigote Cultures of Leishmania tropica and Leishmania donovani
  94. Polyamine synthesis and levels during the growth and replication of Leishmania tropica minor and Leishmania aethiopica
  95. Leishmania donovani: Physicochemical, immunological, and biological characterization of excreted factor from promastigotes
  96. Analysis by SDS-polyacrylamide gel electrophoresis of an immunologically active factor of Leishmania tropica from growth media, promastigotes, and infected macrophages
  97. Plasmodium berghei: Relationship between mitosis and erythropoiesis in spleen cells of infected rats
  98. Isolation of a carbohydrate‐rich immunologically active factor from cultures of Leishmania tropica
  99. Trypanosoma lewisi, T. acomys and T. cruzi: A method for their cultivation with mammalian tissue
  100. Promotion of leishmanial infections in non-permissive host macrophages by conditioned medium
  101. Morphology and the differentiation of leishmanias
  102. Nutritional and immunological factors in the control of infections with Trypanosoma lewisi
  103. Trypanosoma lewisi: Immunohematopoietic interrelationships of the infection in normal, hypoxic, and rebound animals
  104. Trypanosoma lewisi: Electron microscopy of the infected spleen
  105. THERAPEUTIC INTERFERENCE STUDIES: MECHANISMS OF INTERPOLYMER COMPETITION FOR DYES*
  106. Trypanosoma lewisi: Immune spleen cell transfer in rats
  107. Trypanosoma lewisi: In vitro behavior of rat spleen cells
  108. Chromatographic separation of a rat serum growth factor required by Trypanosoma lewisi
  109. Influence of structural factors in the acridines upon their therapeutic effectiveness. Quantum mechanical parameters
  110. Interactions between acridines and triphenyl methane dyes: Their possible role in therapeutic interference
  111. Mouse serum as an environment for the growth of Trypanosoma lewisi
  112. Some relationships between Chlorohydra, its symbionts and some other chlorophyllous forms
  113. Alterations in Fatty Acid Metabolism and Morphology of Leishmania enriettii Exposed to Elevated Temperature
  114. Identity of trypanosome growth factors in serum II. Active globulin components
  115. Regulation of cell membrane permeability in Trypanosoma lewisi
  116. Temperature effect on Leishmania enriettii in vitro
  117. Synthesis of α-Linolenic Acid by Leishmania enriettii
  118. Effects of temperature on morphologic variation of Schizotrypanum cruzi in tissue culture
  119. Peace-Corps Physicians
  120. Excessive Variation in Radiation-induced Chromosome Aberrations
  121. The Evaluation of X-ray-induced Chromosome Aberrations in Cell-cultures of the Chinese Hamster
  122. Absorption Microscopy of Enzymatically Treated Cell-Free Chloroplasts
  123. Effects of Some Metabolic Inhibitors on the Pigments of Euglena gracilis in an Acidic Medium
  124. A Pheophytin‐like Pigment in Dark‐Adapted Euglena gracilis
  125. Biochemical and physiological differentiation during morphogenesis. XIX. Alkaline phosphatase and aldolase activities in the developing cerebral cortex and liver of the fetal guinea pig
  126. Environmental Factors Affecting Growth and Chlorophyll Synthesis in Euglena.* I. Physical and Chemical. II. The Effectiveness of the Spectrum for Chlorophyll Synthesis.
  127. Historical Trends in the Antimalarial Campaign in Palestine And Israel